Imtiaz, Hassaan Khan, Maimoona Ehsan, Hamid Wahab, Ahsan Rafae, Abdul Khan, Ali Y Jamil, Abdur Sana, Muhammad Khawar Jamal, Abdullah Ali, Taimoor Jaffar
...
Published in
OncoTargets and therapy
Carfilzomib (CFZ) is a proteasome inhibitor currently approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Multiple trials are ongoing to evaluate its efficacy and safety in newly diagnosed multiple myeloma (NDMM). The use of CFZ-based two- or three-drug combination regimens as induction for the management of NDMM is an em...
Yu, Ruili Sun, Tingyi Zhang, Xianwei Li, Zhen Xu, Yang Liu, Kaihua Shi, Yuqian Wu, Xue Shao, Yang Kong, Lingfei
...
Published in
OncoTargets and therapy
Purpose TP53 is the most frequently mutated gene in gastric cancer and it can be potentially used for gastric cancer diagnosis and screening. However, standardized clinical approaches that could accurately and cost-effectively detect TP53 mutations in gastric cancer are largely lagged behind. Patients and Methods We conducted next-generation sequen...
Min, Jie Dong, Fei Wu, Pin Xu, Xiaopei Wu, Yimin Tan, Yanbin Yang, Fan Chai, Ying
Published in
OncoTargets and therapy
Purpose Immunotherapy has made breakthroughs in the treatment of non-small-cell lung cancer (NSCLC); however, only a subset of patients achieved long-term survival, so it is of great importance to find a biomarker of lung cancer thus guide immunotherapy. Studies have shown that the infiltration level of tissue resident memory CD8+ T cells (CD8+ TRM...
Zhu, Xingyu He, Yuqi Wang, Yin Lei, Yan Su, Xiaoxing Liu, Yifan Wu, Shuangxiu He, Zhengfu
Published in
OncoTargets and therapy
Background Approximately 2–7% of patients with non-small cell lung cancer harbor anaplastic lymphoma kinase (ALK) rearrangement events. Of note, typical ALK actionable rearrangements are sensitive to treatment with tyrosine kinase inhibitors (TKIs). However, different types of ALK fusion influence the clinical outcomes of this therapeutic approach....
Zhang, Ling Khadka, Bijay Wu, Jieying Feng, Yashu Long, Bing Xiao, Ruozhi Liu, Jiajun
Published in
OncoTargets and therapy
Introduction Acute myeloid leukemia (AML) is a predominant blood malignancy with high mortality and severe morbidity. AML is affected by microRNAs (miRNAs) loaded in exosomes derived from bone marrow mesenchymal stem cells (BM-MSCs). MiR-425-5p has been reported to participate in different cancer models. However, the function of BM-MSCs-derived exo...
An, Jian-Hong Li, Chun-Yan Chen, Chun-Ya Wu, Jian-Bin Shen, Hong
Published in
OncoTargets and therapy
Purpose Cisplatin is one of the most widely used antineoplastic drugs but has limited therapeutic effects due to nephrotoxicity. The aim of this study was to determine the possible renoprotective effect of the antioxidant raloxifene on cisplatin-induced nephrotoxicity in mice. Materials and Methods Cisplatin-induced acute renal injury was establish...
Hu, Linjun Shan, Xingli Han, Dongdong Guo, Zhaoxia Wang, Huina Xiao, Zejun
Published in
OncoTargets and therapy
Penile squamous cell carcinoma (pSCC) is a rare disease in developed countries. pSCC causes a severe health problem and social burden in developing countries. We reported a 49-year-old male recurrent pSCC patient with medium PD-L1 expression and low TMB. The patient obtained complete response after multimodal therapy (MMT). The clinical manifestati...
Phan, Thi Le Kim, Hyun-Jin Lee, Suk Jun Choi, Moon-Chang Kim, Sung-Hak
Published in
OncoTargets and therapy
Wang, Kang-Xin Cui, Ting-Yun Yang, Xu-Dong Wang, Guo-Qun Jiang, Qiu-Sheng Sun, Hui Jiang, Nan-Yuan Yong, Xiao-Min Shi, Chuan-Bing Ding, Yong-Bin
...
Published in
OncoTargets and therapy
Background The standard treatment for advanced gastric/gastroesophageal junction cancer (AGC/GEJC) is palliative chemotherapy combined with targeted therapy. The SOX regimen (S-1 plus oxaliplatin) is recommended as neoadjuvant or palliative first-line chemotherapy in Asian patients. Apatinib, an oral VEGFR tyrosine kinase inhibitor, is associated w...
Kawai, Koji Tawada, Akinobu Onozawa, Mizuki Inoue, Takamitsu Sakurai, Hiromichi Mori, Ichiro Takiguchi, Yuichi Miyazaki, Jun
Published in
OncoTargets and therapy
Testicular germ cell tumor (TGCT) is highly chemo-sensitive cancer; however, there is no established treatment for TGCT relapsed after multiple chemotherapy. Although pembrolizumab showed durable stable disease in some patients, no reliable biomarker for predicting response is available. High microsatellite instability (MSI) is rare in chemo-naïve ...
